
|Articles|November 20, 2013
- Immunotherapy (Issue 1)
- Volume 1
- Issue 1
PD-1 and PD-L1 Antibodies in Lung Cancer
Author(s)Naiyer Rizvi, MD
Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan-Kettering Cancer Center, discusses PD-1 and PD-L1 antibodies in development for the treatment of lung cancer.
Advertisement
Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan-Kettering Cancer Center, discusses PD-1 and PD-L1 antibodies in development for the treatment of lung cancer.
Read about predictive biomarkers of
Articles in this issue
about 12 years ago
MPDL3280A Induces Durable Responses in NSCLC, Other Cancersabout 12 years ago
Immunotherapy—An Increasingly Important Role in Oncologyabout 12 years ago
Suzanne Topalian, MD, on PD-1 Targeted Therapyabout 12 years ago
Understanding Immunotherapy in Cancer: A Q&A with Antoni Ribas, MD, PhDabout 12 years ago
Checkpoint Inhibitors in Cancer Careabout 12 years ago
Search for Predictive Biomarkers of PD-1 Pathway Blockadeabout 12 years ago
Nivolumab Plus Ipilimumab in Advanced Melanomaabout 12 years ago
The Outlook for ImmunotherapiesAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















